27. A pharmaceutical composition, comprising an effective amount of a compound of any of claims 1-26 or 40-57, in a pharmaceutically acceptable carrier.

28. The pharmaceutical composition of claim 27, wherein the composition is suitable for topical delivery.

29. Use of a compound of any of claims 1-26 or 40-57, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier for manufacturing a medicament for the treatment of human papillomavirus in a host infected thereof.

30. The use of claim 29, wherein the human papillomavirus is selected from the group consisting of HPV-16, HPV-18, HPV-31, HPV-33, HPV-35, HPV-39, and HPV-45.

31. The use of claim 29, wherein the human papillomavirus is selected from the group consisting of HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, HPV-68, HPV-73, and HPV-82.

32. The use of claim 30, wherein the human papillomavirus is HPV-16.

33. The use of claim 30, wherein the human papillomavirus is HPV-18.


34. The use of claim 29, wherein the host is a human.

35. The use of claim 30, wherein the host is a human.

36. The use of claim 31, wherein the host is a human.

37. The use of claim 32, wherein the host is a human.


38. Use of a compound having the structure:



,

or its pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment of a papillomavirus infection.


39. Use of a compound having the structure:



,


or its pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment of a papillomavirus infection.

40. A compound of Formula (I)




or a pharmaceutically acceptable salt thereof;


wherein

B^1 is ;

Z^1 and Z^2 are independently selected from oxygen or NR^Z;

R^Z is hydrogen or $C_{1\text{-}4}$alkyl;

R^1 is selected from hydrogen, $C_{1\text{-}24}$alkyl, $C_{2\text{-}24}$alkenyl, $-(CHR^4)_a\text{-}O\text{-}C_{1\text{-}24}$alkyl, $-(CHR^4)_b\text{-}O\text{-}C_{2\text{-}24}$alkenyl, aryl, aryl($C_{1\text{-}4}$alkyl)-, heteroaryl, and ;



R^2 is selected from $C_{1\text{-}24}$alkyl, $C_{2\text{-}24}$alkenyl, $-(CHR^4)_a\text{-}O\text{-}C_{1\text{-}24}$alkyl, $-(CHR^4)_b\text{-}O\text{-}C_{2\text{-}24}$alkenyl, aryl, aryl($C_{1\text{-}4}$alkyl)-, and ;

R^3 is selected from $C_{1\text{-}6}$alkyl and $C_{3\text{-}6}$cycloalkyl;

R^4 is selected from hydrogen, $-(CH_2)_c$-S-$C_{1\text{-}24}$alkyl and $-O-(CH_2)_d-R^{4A}$;

R^{4A} is selected from hydrogen, $C_{1\text{-}24}$alkyl, and aryl;

R^9 is selected from hydrogen and $C_{1\text{-}6}$alkyl;

R^{10} is selected from hydrogen, $C_{1\text{-}6}$alkyl, $-CH_2SH$, $-CH_2CH_2(C=O)NH_2$, $-CH_2CH_2SCH_3$, $-CH_2-$phenyl, $-CH_2OH$, $-CH(OH)CH_3$, , $-CH_2(C=O)OH$, $-CH_2CH_2(C=O)OH$, $-(CH_2)_3NH(C=NH)NH_2$, , and $-(CH_2)_4NH_2$;

R^{11} is selected from hydrogen, $C_{1\text{-}8}$alkyl, cycloalkyl, aryl, and aryl($C_{1\text{-}6}$alkyl)-;

a and b are independently selected from 1, 2, 3, or 4;

c and d are independently selected from 0, 1, 2, or 3.

41. The compound of claim 40, wherein R^3 is methyl.

42. The compound of claim 40 or 41, wherein Z^1 is oxygen and Z^2 is oxygen.

43. The compound of claim 40 or 41,
wherein
Z^1 is oxygen;
Z^2 is NR^Z; and
R^Z is hydrogen.


44. The compound of claim 40, 41, 42, or 43
wherein
R^1 is $-(CHR^4)_a$-O-$C_{1\text{-}24}$alkyl;
R^4 is hydrogen; and
a is 2.

45. The compound of claim 40, 41, 42, 43, or 44, wherein R^2 is aryl.

46. The compound of claim 45, wherein R^2 is phenyl or benzyl.

47. The compound of claim 40, 41, 43, 45, or 46

wherein


R^1 is ;

R^9 is hydrogen;

R^{10} is methyl; and


R^{11} is methyl or ethyl.

48. The compound of claim 40 of the structure:




or a pharmaceutically acceptable salt thereof.

49. The compound of claim 40 of the structure:




or a pharmaceutically acceptable salt thereof.

50. The compound of claim 40 of the structure:




or a pharmaceutically acceptable salt thereof.

51. A compound of Formula (I)



or a pharmaceutically acceptable salt thereof;


wherein


B^1 is ;

Z^1 is oxygen;

Z^2 is NR^Z;

R^Z is hydrogen or C_{1-4}alkyl;

R^1 is selected from hydrogen, C_{1-24}alkyl, C_{2-24}alkenyl, -$(CHR^4)_a$-O-C_{1-24}alkyl, -$(CHR^4)_b$-O-C_{2-24}alkenyl, aryl, aryl(C_{1-4}alkyl)-, heteroaryl, and ;


R^2 is selected from C_{1-24}alkyl, C_{2-24}alkenyl, -$(CHR^4)_a$-O-C_{1-24}alkyl, -$(CHR^4)_b$-O-C_{2-24}alkenyl, aryl, aryl(C_{1-4}alkyl)-, and ;


R^3 is selected from C_{1-6}alkyl and C_{3-6}cycloalkyl;

R^4 is selected from hydrogen, -$(CH_2)_c$-S-C_{1-24}alkyl and –O-$(CH_2)_d$-R^{4A};

R^{4A} is selected from hydrogen, C_{1-24}alkyl and aryl;

R^9 is selected from hydrogen and C_{1-6}alkyl;

R^{10} is selected from hydrogen, C_{1-6}alkyl, -CH_2SH, -$CH_2CH_2(C=O)NH_2$, -$CH_2CH_2SCH_3$, -CH_2-phenyl, -CH_2OH, -$CH(OH)CH_3$, 

, -$CH_2(C=O)OH$, -$CH_2CH_2(C=O)OH$, -$(CH_2)_3NH(C=NH)NH_2$, 


, and –$(CH_2)_4NH_2$;

R^{11} is selected from hydrogen, C_{1-8}alkyl, cycloalkyl, aryl, and aryl(C_{1-6}alkyl)-;

a and b are independently selected from 1, 2, 3, or 4;

c and d are independently selected from 0, 1, 2, or 3.

52. The compound of claim 51, wherein R^Z is hydrogen.

53. The compound of claim 51 or 52, wherein R^1 is 


.

54. The compound of claim 53,
wherein
R^9 is hydrogen;
R^{10} is methyl; and
R^{11} is methyl or ethyl.

55. The compound of claim 51, 52, 53, or 54, wherein R^2 is aryl.

56. The compound of claim 55, wherein R^2 is phenyl or benzyl.

57. The compound of claim 51 of the structure:



or a pharmaceutically acceptable salt thereof.